17 th July 2016 Chennai, Tamil Nadu India

Transcription

1 17 th July 2016 Chennai, Tamil Nadu India "Dia League was held at Chennai, Tamil Nadu, India. The CME was organized by of Asian Society of Continuing Medical Education. The sole objective of the CME was to update the practicing doctors about Diabetes mellitus, level of morbidity and mortality due to diabetes and its associated spectrum of complications and diabetes management as the disease is now highly visible across all societies within India. The session was open with an introductory session by Asian Society of Continuing Medical Education and followed by the scientific agenda. Date : 17 th July Venue : Grand by GRT, Chennai, Tamil Nadu, India. Total Participants : 67 TOPICS : The Role of Combination therapies in early, intensive management of newly diagnosed Type 2 Diabetes with Marked Glycaemia. SU Re Emphasized. DDP- 4 Inhibitors are they different? Addressing the CV risk in type 2 DM. PPHG Clinical Significance and management. Overcoming Barrier s in intensifying oral therapies role of SGLT2 inhibitors. Work Shop on AGP. Current advancement done in the field of Diabetes

2 Faculties Dr. Shyam Sunder Kalavalappalli MBBS, MRCP (U.K.), CCT, FRCP, MRCP (Diab. & Endo) Director and Head of the Department, Department of Diabetes, Endocrinology and Bariatrics at Sunshine Hospitals Dr. G. Shanmugasundar M.B.B.S., MD (Gen Med), DM (Endo) Consultant Endocrinologist ESI Medical College & PGIMSR, KK Nagar, Chennai & Director MAGNA CODE (Clinics for Obesity Diabetes & Diabetes) Dr. Samith A. Shetty MBBS, MDRC, PGDD, Fellowship in Epidemiology Consultant Diabetologist, Sparsh Hospitals Bangalore Dr. Manohar Kathige Nageshappa MBBS, MD, DNB, MRCP Consultant Diabetologist at Sharada Medical Center in Kalyan Nagar, Bangalore & Manipal Hospital, Bangalore Dr. T. Palaniappan MD, DNB, MNAMS, MRCP (LONDON), MRCP (EDINGBURGH) INTERNAL MEDICINE CEO & Director Medway Medical Centre Dr. Shyam Mukundan MBBS, MD (General Medicine), PG Diploma in Diabetology Consultant Diabetologist, Lakshmi Hospital, Kerala Dr. S. Socrates M.B.B.S., MD (Gen Med), DM (Cardio) Consultant Diabetologist and Cardiologist for the past 12 years in Chennai Dr. S. Venkataraman MBBS, MD Senior most Diabetologist at Apollo Hospitals and is one of the very few surgeons in India who conducts reconstructive surgeries for patients with deformed neuropathic foot and ankles.

3 1. Dr. Shyam Sunder Kalavalapalli talked on the role of combination therapies in early, Intensive management of newly diagnosed Type 2 Diabetes with marked glycaemia. Highlighted Decision point: Which of the options would you choose for this patient? Highlighted Diabetes Remission after Intensive Insulin Therapy in New Onset T2DM. Highlighted Insulin and its Barriers. Early combination therapy for the treatment of type 2 DM: Systematic Review and Meta analysis. Highlighted Initial Management of severe Hyperglycemia in patients with Type 2 Diabetes: An Observational Study. The ideal components for combination therapy? Need for an early and combination approach to type 2 diabetes management. 2. Dr. Samith A. Shetty talked on SU re emphasized Insulin Secretion (Glimepiride). Showed Therapeutic actions Attributes of sulfonylureas IDF Global Guideline for Type 2 Diabetes. ADA and EASD algorithm for the management of type 2 diabetes. Type 2 Diabetes is a Dual Problem

4 3. Dr. T. Palaniappan Talked on DPP4 inhibitors are they different? Decreased Insulin, Elevated Glucagon, and Hyperglycemia in Type 2 Diabetes. Reduced Incretin Effect in Type 2 Diabetic Patients Type 2 Diabetes is a Global Cardio-metabolic Risk (CMR) DPP4 inhibitors (gliptins) is hypoglycemic class that inhibiting the action of DPP4 (which degrade the action of GLP-1 to convert it to inactive form DPP4 inhibitors drugs. Efficacy as Monotherapy compared to Metformin comparable efficacy at 2 yrs. 4. Dr. S. Socrates talked on addressing the CV risk in type 2 DM Cardiac morbidities due to diabetics. (Each morbidities was explained in detailed) o Metabolic Syndrome o Coronary heart disease o Angina o Heart failure o Diabetic Cardiomyopathy Treatment of DM Dyslipidemia 5. Dr. G. Shanmugasundar Talked on PPHG Clinical Significance and management Diabetic with very high level of PPG, rich carbohydrate diet and sedentary lifestyle, the cases were explained to the audience and the whole case was open for discussion. Audience actively participated in the discussion regarding the investigations and treatment. It was a very interactive session and the delegates thoroughly enjoyed it.

5 6. Dr. Manohar Kathige Nageshappa Talked on Overcoming barrier s in Intensifying therapies- role of SGLT2 inhibitors Unmet Needs With Conventional Antihyperglycemic Therapies The Kidneys Play an Important Role in Glucose Control. Rationale for SGLT2 Inhibitors. Effects of SGLT2 Inhibitors SGLT2 Inhibitors in Phase 3 Development. Empagliflozin: Change in Plasma Glucose in the Fasting State. Changes from Baseline in Fasting Plasma Glucose in Phase 3 Dapagliflozin Studies. Glycosuria : Weight loss and BP reduction Reduction In Leptin/Adiponectin Ratio. 7. Dr. Shyam Mukundan talked on -Workshop on Ambulatory glucose profiling. Rationale for Ambulatory Glucose Profile (AGP) The AGP 14-day Profile The key benefits of the 14-day AGP graph. Consensus Recommendations for use of AGP in clinical practice. Flash Glucose Monitoring The FreeStyleLibre Pro system FreeStyleLibre Pro sensor features Measuring glucose levels in interstitial fluid (ISF) FreeStyleLibre Pro software features Conventional CGM Traces Interpreting the AGP Graph

6 8. Dr. S. Venkataraman talked on Current advancement done in the field of Diabetes - Insulin Jet Injectors Continuous Glucose Monitoring System (CGMS) REAL-Time Continuous Glucose Monitoring System CGM in T1DM: JDRF Sensor Trial.

7 SNAPSHOTS